Findings of Research Misconduct, 47253 [E9-22118]

Download as PDF Federal Register / Vol. 74, No. 177 / Tuesday, September 15, 2009 / Notices sroberts on DSKD5P82C1PROD with NOTICES National Historic Landmark if DHS’ offices extended across both the West and East Campuses. St. Elizabeths was listed in the National Register on April 26, 1979, designated a National Historic Landmark on December 14, 1990, and received District of Columbia Historic District Designation in May of 2005. As part of its November 7, 2008 Final EIS, GSA considered an alternative, Alternative 5, which assessed placing development on both campuses to create a unified DHS Headquarters. GSA issued a Record of Decision on December 16, 2008, for the project Master Plan to consolidate 3.8 million GSF of secure office and shared use space, plus parking, on the St. Elizabeths West Campus. As part of the Final EIS for this action, GSA also assessed, on a programmatic level, the impacts of constructing 750,000 GSF of office plus associated parking on the St. Elizabeths East Campus. GSA noted in its Record of Decision that an EIS tiered to the November 7, 2008 Final EIS would be prepared for the East Campus in accordance with 40 CFR 1502.20 and 1502.28. The National Capital Planning Commission approved the project Master Plan incorporating Alternative 5 on January 8, 2009. Scoping Process In accordance with NEPA, a scoping process will be conducted to (i) aid in determining the alternatives to be considered and the scope of issues to be addressed, and (ii) identify the significant issues related to the amended Master Plan for the DHS consolidation at St. Elizabeths. ‘‘Scoping’’ is a tool for identifying the issues that should be addressed in the EIS and Section 106 consultation process. Scoping allows the public to help define priorities and express stakeholder and community issues to the agency through oral and written comments as described in 40 CFR part 1500.1(b). Scoping will be accomplished through a public scoping meeting, direct mail correspondence to potentially interested persons, agencies, and organizations, and meeting with agencies having an interest in the amended Master Plan. It is important that Federal, regional and local agencies, and interested individuals and groups take this opportunity to identify environmental concerns that should be addressed during the preparation of the Draft EIS. GSA is also using the NEPA scoping process to facilitate consultation with the public under Section 106 of the National Historic Preservation Act (36 CFR part 800 (Protection of Historic Properties)). GSA welcomes comments VerDate Nov<24>2008 19:12 Sep 14, 2009 Jkt 217001 from the public to ensure that it takes into account the effects of its action on historic and cultural resources. Public Scoping Meeting The public scoping meeting will be held on October 8, 2009, from 6 to 8:30 p.m., at the Matthews Memorial Baptist Church, John H. Kearney, Sr. Fellowship Hall, located at 2616 Martin Luther King, Jr. Avenue, SE. in Southeast Washington, DC. The meeting will be an informal open house, where visitors may come, receive information, and give comments. GSA will publish notices in the Washington Post, Washington Times, and East of the River (Capital Community News) announcing this meeting approximately one to two weeks prior to the meeting. After scoping comments are received, GSA will prepare a scoping report, available to the public, which will summarize the comments received for incorporation into the EIS and Section 106 processes. Written Comments Agencies and the public are encouraged to provide written comments on the scoping issues in addition to or in lieu of giving their comments at the public scoping meeting. Written comments regarding the environmental analysis for the amended Master Plan must be postmarked no later than October 16, 2009, and sent to the following address: General Services Administration, National Capital Region, Attention: Denise Decker, NEPA Lead, 301 7th Street, SW., Room 7600, Washington, DC 20407. Fax (202) 708–7671. denise.decker@gsa.gov. Dated: September 9, 2009. Patricia T. Ralston, Director, Portfolio Management, National Capital Region, Public Buildings Service. [FR Doc. E9–22224 Filed 9–14–09; 8:45 am] BILLING CODE 6820–23–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Findings of Research Misconduct Office of the Secretary, HHS. Notice. AGENCY: ACTION: (UCC) and additional analysis and information obtained by the Office of Research Integrity (ORI) during its oversight review, ORI found that Jennifer N. Arriaga, former Research Assistant in a clinical trial project entitled Brief Strategic Family Therapy for Adolescent Drug Abusers (BSFT) at UCC, engaged in research misconduct in research funded by National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), cooperative agreement U10 DA13720. Specifically, ORI found that Ms. Arriaga knowingly and intentionally engaged in research misconduct by fabricating 17 interviews and falsifying 10 subject incentive receipts in the BSFT. The interview record consisted of Timeline Follow Back information, confidentiality self-report forms, and urine drug test results. The following administrative actions have been implemented for a period of two (2) years, beginning on August 18, 2009: (1) Ms. Arriaga is debarred from eligibility for any contracting or subcontracting with any agency of the United States Government and from eligibility or involvement in nonprocurement programs of the United States pursuant to HHS’ Implementation (2 CFR part 276 et seq.) of OMB Guidelines to Agencies on Governmentwide Debarment and Suspension (2 CFR part 180); and (2) Ms. Arriaga is prohibited from serving in any advisory capacity to the U.S. Public Health Service (PHS), including but not limited to service on any PHS advisory committee, board, and/or peer review committee, or as a consultant. FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852. (240) 453–8800. John Dahlberg, Director, Division of Investigative Oversight, Office of Research Integrity. [FR Doc. E9–22118 Filed 9–14–09; 8:45 am] BILLING CODE 4150–31–P SUMMARY: Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case. Jennifer N. Arriaga, Universidad Central Del Caribe: Based on the findings of an investigation report by the Universidad Central Del Caribe PO 00000 Frm 00069 Fmt 4703 Sfmt 4703 47253 E:\FR\FM\15SEN1.SGM 15SEN1

Agencies

[Federal Register Volume 74, Number 177 (Tuesday, September 15, 2009)]
[Notices]
[Page 47253]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-22118]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case.
    Jennifer N. Arriaga, Universidad Central Del Caribe: Based on the 
findings of an investigation report by the Universidad Central Del 
Caribe (UCC) and additional analysis and information obtained by the 
Office of Research Integrity (ORI) during its oversight review, ORI 
found that Jennifer N. Arriaga, former Research Assistant in a clinical 
trial project entitled Brief Strategic Family Therapy for Adolescent 
Drug Abusers (BSFT) at UCC, engaged in research misconduct in research 
funded by National Institute on Drug Abuse (NIDA), National Institutes 
of Health (NIH), cooperative agreement U10 DA13720.
    Specifically, ORI found that Ms. Arriaga knowingly and 
intentionally engaged in research misconduct by fabricating 17 
interviews and falsifying 10 subject incentive receipts in the BSFT. 
The interview record consisted of Timeline Follow Back information, 
confidentiality self-report forms, and urine drug test results.
    The following administrative actions have been implemented for a 
period of two (2) years, beginning on August 18, 2009:
    (1) Ms. Arriaga is debarred from eligibility for any contracting or 
subcontracting with any agency of the United States Government and from 
eligibility or involvement in nonprocurement programs of the United 
States pursuant to HHS' Implementation (2 CFR part 276 et seq.) of OMB 
Guidelines to Agencies on Governmentwide Debarment and Suspension (2 
CFR part 180); and
    (2) Ms. Arriaga is prohibited from serving in any advisory capacity 
to the U.S. Public Health Service (PHS), including but not limited to 
service on any PHS advisory committee, board, and/or peer review 
committee, or as a consultant.

FOR FURTHER INFORMATION CONTACT: Director, Division of Investigative 
Oversight, Office of Research Integrity, 1101 Wootton Parkway, Suite 
750, Rockville, MD 20852. (240) 453-8800.

John Dahlberg,
Director, Division of Investigative Oversight, Office of Research 
Integrity.
[FR Doc. E9-22118 Filed 9-14-09; 8:45 am]
BILLING CODE 4150-31-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.